A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Chen, Yuan , Ph.D. Bookmark and Share

Yuan Chen, Ph.D. Research

 
Ubiquitin-like Modifications
Our current research interest is in protein modifications by a family of small proteins known as ubiquitin and its homologues. These modifications control life spans, trafficking, assembly and enzymatic activities of cellular proteins, and are important in nearly every aspect of biological functions. We employ a combination of structural, biochemical, molecular and cellular biological methods to understand these processes in cellular regulation and disease pathogenesis. Specific areas of interest are outlined below.

The Role of SUMOylation in Oncogenesis
Post-translational modifications by the small ubiquitin-like modifiers (SUMO) are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. For example, knocking down of the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, has the strongest synthetic lethal interaction with Myc hyperactivation. We are investigating the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations. In addition, we are investigating the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70 percent of all human cancers, and KRas is also frequently mutated in human cancers.

SUMO Modifications and HIV Replication
SUMO-specific proteases (SENP) regulate post-translational modifications by SUMO through catalyzing the maturation of SUMO precursors and the removal of SUMO from modified proteins. Small molecule inhibitors of SENPs that function in cells would be valuable tools for elucidating the functions of SENPs. We have recently identified a family of small molecule inhibitors of SENPs that inhibit de-SUMOylation activities in cells. Coincidently, these small molecules had been shown to confer anti-HIV activities in a National Cancer Institute antiviral screen, although the cellular targets and the mechanism of inhibition of HIV were unknown. We are investigating the molecular mechanism of how SUMOylation is involved in HIV life cycle. In addition, we are conducting the structure-activity relationship studies of how these inhibitors interact with the SENPs and inhibit their enzymatic activity, and use this information to develop improved inhibitors. Furthermore, we are interested in exploiting this pathway to develop a potential strategy for a cure of HIV by allowing the immune system to target HIV infected cells without producing infectious virus.

NMR-based Metabolomics
Metabolic activity is a reflection of cellular functions. Our laboratory utilizes nuclear magnetic resonance (NMR) spectroscopy as tools for metabolomic studies, that is, global analysis of metabolic activities. Our goal is to provide information on cellular pathways to understand metabolic dysfunctions of cancer cells.

Application of NMR Methods in Drug Discovery
We are collaborating with several other laboratories with expertise in synthetic chemistry, molecular biology and medical oncology to develop new therapeutics for cancer. State-of-the-art NMR methods are employed to provide information on protein-ligand interactions at an atomic resolution; information that is critical for the rational design of new therapeutics.
 
Representative Publications:
 
Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation
YJ Li, AL Perkins, Y Su, Y Ma, L Colson, DA Horne, Y Chen
Proceedings of the National Academy of Sciences 109 (11), 4092-4097, 2012
 
The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications
J Wang, W Hu, S Cai, B Lee, J Song, Y Chen
Molecular cell 27 (2), 228-237, 2007
 
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins
Jing Song, Linda K Durrin, Thomas A Wilkinson, Theodore G Krontiris, Yuan Chen
Proceedings of the National Academy of Sciences of the United States of America, 101 (40), 14373-14378, 2004
 
More publications can be found at:
http://scholar.google.com/citations?user=zgAR9fsAAAAJ&hl=en
 

Yuan Chen, Ph.D. Facilities

NMR Facility
 
Computers and Software
  • Six Linex workstations
  • Two multi-processor servers
  • Software include: InsightII, FELIX, NMRVIEW, NMRDRAW, PIPE, MOLMOL, DYANA, CNS, ARIA, HADDOCK and AMBER.
 
Other Shared Equipment
  • Isothermal titration calorimeter
  • Jasco CD instrument
  • Automated Applied Biosystems (AB) Procise Protein Sequencing System for N-terminal Edman degradation
  • A Perkin Applied Biosystems Procise C-terminal sequencer and a Hewlett Packard C-terminal sequencer
  • Dionex AAA Direct amino acid analyzer
  • HPLC systems suitable for narrow-bore and microcapillary chromatography and equipped for detection of peptides at 214 nm as well as variable wavelength fluorescence detection
  • Pharmacia FPLC for protein purification
  • Perkin-Elmer FTIR
  • Hitachi UV/VIS Spectrophotometer
  • Pharmacia BIAcoreTM System
  • PerSeptive Biosystems BioCAD/SPRINT
  • Bio-Rad scanning Densitometer
  • Three Thermo Finnigan LCQ family ion traps (two Classic and one Deca) equipped with electrospray/LC sources.
  • An Applied Biosystems Mariner electrospray (ES) Orthogonal TOF spectrometer
  • Applied Biosystems Voyager DE STR MALDI-TOF spectrometer
  • Scintillation and gamma counters
  • Wallac Micro Beta counter
  • Tomtec 96-well plate harvester
 

Lab Members

 
Current Lab Members

Shannon Maldonado
Senior Administrative Analyst
 
Ramir Vega
Research Associate
 
Grace Aldana-Masangkay, Ph.D.
Research Fellow
 
Aileen Alontaga, Ph.D.
Research Fellow
 
Nigus D Ambaye, Ph.D.
Research Fellow

Chih-Hong Chen, Ph.D.
Research Fellow

Li Du, Ph.D.
Research Fellow
 
Yi-Jia Li, Ph.D.
Staff Scientist
 
Alumni

Postdoctoral fellows
Yate-Ching Yuan, Ph.D.
Director of the Bioinformatic Core Facility at Beckman Research Institute of City of Hope

Maria Victoria Botuyan, Ph.D.
Staff scientist at Mayo Clinic, MN, USA

Jerry Hu, Ph.D.
Manager, Materials Research Laboratory Spectroscopy Facility, UC Santa Barbara

Donghai Lin, Ph.D.
Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Suhkmann Kim, Ph.D.
Associate Professor at Pusan National University, Korea. 

Sheng Cai, Ph.D.
Director of the NMR laboratory at Marquette University, Wisconsin, USA

Lingyang Zhu, Ph.D.
Senior Scientist, Array BioPharma Inc. Boulder, CO

Thomas Wilkinson, Ph.D.
Staff Scientist, UCLA

Xuanjun Ai, Ph.D.
Postdoctoral fellow with Dr. Charalampos Kalodimos at Rutgers University
 
Ikenna Madu, Ph.D.
Scientist Kineta, Inc, Seattle, WA
 
Yang Su, Ph.D.
Beijing, China
 
Jianghai Wang, Ph.D.
Senior Scientist, BostonBiochem, MA, USA
 
Yifei Li, Ph.D.
NCI at Frederick, Frederick, MD
 
Graduate students
Ziming Zhang, Ph.D. (2004)
Director of the Nuclear Magnetic Resonance Core, University of South Florida

Jing Song, Ph.D. (2006)
Jing spent two years as a postdoctoral fellow with Professor Timothy Springer at Harvard Medical School, and now is group leader at BioDuro.

Khue Truong, Ph.D. (2012)
Post doctoral fellow at UCLA.

Research technicians
Qin Liu, M.S., Biomolecular NMR Facility manager, Department of Biochemistry, University of Western Ontario, Canada

Candace Seu, Ph.D. student, UC San Diego

Lisa Fukui, M.D/Ph.D. student, University of Illinois at Urbane Champion

Brian Lee, medical student, SUNY Stony Brook

Larry Tong, medical student, University of Nebraska

Steven Wong, medical student, UCLA
 

Yuan Chen, Ph.D. NvMap Agreement Download

Academic (nonprofit) License Agreement
 
Please send two signed originals of the license agreement to:
 
City of Hope
1500 East Duarte Road
Duarte, California 91010
Attn.:  Director, Office of Technology Licensing
Fax: 626-301-8175
 
With a copy to:
 
Dr. Yuan Chen
Department of Molecular Medicine
City of Hope
1500 East Duarte Road
Duarte, California 91010
Fax: 626-301-8186
 
Industry License Agreement
 
For more information please contact:
 
Matthew Grunseth, M.B.S.
Technology Licensing Manager
mgrunseth@coh.org
 

Chen, Yuan , Ph.D.

Yuan Chen, Ph.D. Research

 
Ubiquitin-like Modifications
Our current research interest is in protein modifications by a family of small proteins known as ubiquitin and its homologues. These modifications control life spans, trafficking, assembly and enzymatic activities of cellular proteins, and are important in nearly every aspect of biological functions. We employ a combination of structural, biochemical, molecular and cellular biological methods to understand these processes in cellular regulation and disease pathogenesis. Specific areas of interest are outlined below.

The Role of SUMOylation in Oncogenesis
Post-translational modifications by the small ubiquitin-like modifiers (SUMO) are important in oncogenesis and cellular response to DNA damage. Recent findings indicate that the key oncogenic pathways driven by Myc and KRas are dependent on, or addicted to, SUMOylation. For example, knocking down of the gene encoding the catalytic subunit of the SUMO activating enzyme (SAE), SAE2, has the strongest synthetic lethal interaction with Myc hyperactivation. We are investigating the molecular mechanisms underlying the synthetic lethality of SUMOylation with Myc hyperactivation and KRas mutations. In addition, we are investigating the structure-activity relationship of how the inhibitors interact with the SAE and inhibit its enzymatic activity, and use this information to guide further improvement of the inhibitors. These studies could potentially improve treatment of many cancers, as overexpression of Myc is estimated to contribute to 70 percent of all human cancers, and KRas is also frequently mutated in human cancers.

SUMO Modifications and HIV Replication
SUMO-specific proteases (SENP) regulate post-translational modifications by SUMO through catalyzing the maturation of SUMO precursors and the removal of SUMO from modified proteins. Small molecule inhibitors of SENPs that function in cells would be valuable tools for elucidating the functions of SENPs. We have recently identified a family of small molecule inhibitors of SENPs that inhibit de-SUMOylation activities in cells. Coincidently, these small molecules had been shown to confer anti-HIV activities in a National Cancer Institute antiviral screen, although the cellular targets and the mechanism of inhibition of HIV were unknown. We are investigating the molecular mechanism of how SUMOylation is involved in HIV life cycle. In addition, we are conducting the structure-activity relationship studies of how these inhibitors interact with the SENPs and inhibit their enzymatic activity, and use this information to develop improved inhibitors. Furthermore, we are interested in exploiting this pathway to develop a potential strategy for a cure of HIV by allowing the immune system to target HIV infected cells without producing infectious virus.

NMR-based Metabolomics
Metabolic activity is a reflection of cellular functions. Our laboratory utilizes nuclear magnetic resonance (NMR) spectroscopy as tools for metabolomic studies, that is, global analysis of metabolic activities. Our goal is to provide information on cellular pathways to understand metabolic dysfunctions of cancer cells.

Application of NMR Methods in Drug Discovery
We are collaborating with several other laboratories with expertise in synthetic chemistry, molecular biology and medical oncology to develop new therapeutics for cancer. State-of-the-art NMR methods are employed to provide information on protein-ligand interactions at an atomic resolution; information that is critical for the rational design of new therapeutics.
 
Representative Publications:
 
Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation
YJ Li, AL Perkins, Y Su, Y Ma, L Colson, DA Horne, Y Chen
Proceedings of the National Academy of Sciences 109 (11), 4092-4097, 2012
 
The intrinsic affinity between E2 and the Cys domain of E1 in ubiquitin-like modifications
J Wang, W Hu, S Cai, B Lee, J Song, Y Chen
Molecular cell 27 (2), 228-237, 2007
 
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins
Jing Song, Linda K Durrin, Thomas A Wilkinson, Theodore G Krontiris, Yuan Chen
Proceedings of the National Academy of Sciences of the United States of America, 101 (40), 14373-14378, 2004
 
More publications can be found at:
http://scholar.google.com/citations?user=zgAR9fsAAAAJ&hl=en
 

Facilities

Yuan Chen, Ph.D. Facilities

NMR Facility
 
Computers and Software
  • Six Linex workstations
  • Two multi-processor servers
  • Software include: InsightII, FELIX, NMRVIEW, NMRDRAW, PIPE, MOLMOL, DYANA, CNS, ARIA, HADDOCK and AMBER.
 
Other Shared Equipment
  • Isothermal titration calorimeter
  • Jasco CD instrument
  • Automated Applied Biosystems (AB) Procise Protein Sequencing System for N-terminal Edman degradation
  • A Perkin Applied Biosystems Procise C-terminal sequencer and a Hewlett Packard C-terminal sequencer
  • Dionex AAA Direct amino acid analyzer
  • HPLC systems suitable for narrow-bore and microcapillary chromatography and equipped for detection of peptides at 214 nm as well as variable wavelength fluorescence detection
  • Pharmacia FPLC for protein purification
  • Perkin-Elmer FTIR
  • Hitachi UV/VIS Spectrophotometer
  • Pharmacia BIAcoreTM System
  • PerSeptive Biosystems BioCAD/SPRINT
  • Bio-Rad scanning Densitometer
  • Three Thermo Finnigan LCQ family ion traps (two Classic and one Deca) equipped with electrospray/LC sources.
  • An Applied Biosystems Mariner electrospray (ES) Orthogonal TOF spectrometer
  • Applied Biosystems Voyager DE STR MALDI-TOF spectrometer
  • Scintillation and gamma counters
  • Wallac Micro Beta counter
  • Tomtec 96-well plate harvester
 

Lab Members and Alumni

Lab Members

 
Current Lab Members

Shannon Maldonado
Senior Administrative Analyst
 
Ramir Vega
Research Associate
 
Grace Aldana-Masangkay, Ph.D.
Research Fellow
 
Aileen Alontaga, Ph.D.
Research Fellow
 
Nigus D Ambaye, Ph.D.
Research Fellow

Chih-Hong Chen, Ph.D.
Research Fellow

Li Du, Ph.D.
Research Fellow
 
Yi-Jia Li, Ph.D.
Staff Scientist
 
Alumni

Postdoctoral fellows
Yate-Ching Yuan, Ph.D.
Director of the Bioinformatic Core Facility at Beckman Research Institute of City of Hope

Maria Victoria Botuyan, Ph.D.
Staff scientist at Mayo Clinic, MN, USA

Jerry Hu, Ph.D.
Manager, Materials Research Laboratory Spectroscopy Facility, UC Santa Barbara

Donghai Lin, Ph.D.
Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 

Suhkmann Kim, Ph.D.
Associate Professor at Pusan National University, Korea. 

Sheng Cai, Ph.D.
Director of the NMR laboratory at Marquette University, Wisconsin, USA

Lingyang Zhu, Ph.D.
Senior Scientist, Array BioPharma Inc. Boulder, CO

Thomas Wilkinson, Ph.D.
Staff Scientist, UCLA

Xuanjun Ai, Ph.D.
Postdoctoral fellow with Dr. Charalampos Kalodimos at Rutgers University
 
Ikenna Madu, Ph.D.
Scientist Kineta, Inc, Seattle, WA
 
Yang Su, Ph.D.
Beijing, China
 
Jianghai Wang, Ph.D.
Senior Scientist, BostonBiochem, MA, USA
 
Yifei Li, Ph.D.
NCI at Frederick, Frederick, MD
 
Graduate students
Ziming Zhang, Ph.D. (2004)
Director of the Nuclear Magnetic Resonance Core, University of South Florida

Jing Song, Ph.D. (2006)
Jing spent two years as a postdoctoral fellow with Professor Timothy Springer at Harvard Medical School, and now is group leader at BioDuro.

Khue Truong, Ph.D. (2012)
Post doctoral fellow at UCLA.

Research technicians
Qin Liu, M.S., Biomolecular NMR Facility manager, Department of Biochemistry, University of Western Ontario, Canada

Candace Seu, Ph.D. student, UC San Diego

Lisa Fukui, M.D/Ph.D. student, University of Illinois at Urbane Champion

Brian Lee, medical student, SUNY Stony Brook

Larry Tong, medical student, University of Nebraska

Steven Wong, medical student, UCLA
 

Agreement Download

Yuan Chen, Ph.D. NvMap Agreement Download

Academic (nonprofit) License Agreement
 
Please send two signed originals of the license agreement to:
 
City of Hope
1500 East Duarte Road
Duarte, California 91010
Attn.:  Director, Office of Technology Licensing
Fax: 626-301-8175
 
With a copy to:
 
Dr. Yuan Chen
Department of Molecular Medicine
City of Hope
1500 East Duarte Road
Duarte, California 91010
Fax: 626-301-8186
 
Industry License Agreement
 
For more information please contact:
 
Matthew Grunseth, M.B.S.
Technology Licensing Manager
mgrunseth@coh.org
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Ryan Chavira was a senior in high school when she began feeling sluggish, fatigued and, well, “down.” Trips to the doctor ended in “you’re fine” pronouncements; blood tests results showed nothing of real concern. But Chavira’s grandmother had passed away from ovarian cancer when she was in eig...
  • Brain tumors are exceptionally difficult to treat. They can be removed surgically, but individual cancer cells may have already spread elsewhere in the brain and can escape the effects of both radiation and chemotherapy. To prevent tumors from recurring, doctors need a way to find and stop those invasive cancer...
  • Breast cancer risk is personal; breast cancer risk assessment should be, too. To that end, City of Hope researchers have developed a starting point to help women (and their doctors) with a family history of the disease begin that risk assessment process. The result is an iPhone app, called BRISK, for Breast Can...
  • When it comes to breast cancer, women aren’t limited to getting screened and, if diagnosed, making appropriate treatment choices. They can also take a proactive stance in the fight against breast cancer by understanding key risk factors and practicing lifestyle habits that can help reduce their own breast...
  • Cancers of the blood and immune system are considered to be among the most difficult-to-treat cancers. A world leader in the treatment of blood cancers, City of Hope is now launching an institute specifically focused on treating people with lymphoma, leukemia and myeloma, as well as other serious blood and bone...
  • Genetics, genes, genome, genetic risk … Such terms are becoming increasingly familiar to even nonresearchers as studies and information about the human make-up become more extensive and more critical. At City of Hope, these words have long been part of our vocabulary. Researchers and physicians are studyi...
  • Mammograms are currently the best method to detect breast cancer early, when it’s easier to treat and before it’s big enough to feel or cause symptoms. But recent mammogram screening guidelines may have left some women confused about when to undergo annual testing. Here Lusi Tumyan, M.D., chief of t...
  • Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part dire...
  • The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the ...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...